Drug Profile
SXC 2023
Alternative Names: SXC-2023Latest Information Update: 17 Mar 2021
Price :
$50
*
At a glance
- Originator Marquette University; University of Wisconsin at Milwaukee
- Developer Promentis Pharmaceuticals
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action SLC7A11 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Impulse control disorders
Most Recent Events
- 17 Mar 2021 Phase II development for Impulse control disorders is still ongoing in USA (Promentis Pharmaceuticals pipeline, March 2021)
- 16 Dec 2019 Promentis Pharmaceuticals completes a phase II trial for Impulse control disorders in USA (NCT03797521)
- 31 Oct 2019 Promentis Pharmaceuticals completes enrolment in its phase II trial for Impulse control disorders in USA (NCT03797521)